Metabolic Diseases
XtalPi and DoveTree Announce Landmark $6 Billion AI-Powered Drug Discovery Collaboration
XtalPi; DoveTree Medicines; AI drug discovery; robotics; pharmaceutical R&D; Gregory Verdine; oncology; immunology; neurology; metabolic diseases; collaboration; upfront payment; milestone payments; royalties
Terns to Stop Funding Metabolic Disease Trials Beyond 2025; Seeks Partners for Assets
Terns Pharmaceuticals; metabolic disease; clinical trials; pipeline strategy; partnering; oncology focus; TERN-601; TERN-701; GLP-1 agonists; CML
BioAge Signs Option Agreement for Obesity Asset from Chinese Biotech Following APJ Agonist Setback
BioAge; JiKang Therapeutics; obesity; APJ agonist; option agreement; nanobody; small molecule agonists; exercise mimetic; incretin therapy; metabolic diseases
Pfizer’s Strategic Shift Post-Danuglipron: Exploring New Frontiers in Obesity Treatment
Pfizer, danuglipron, obesity treatment, GLP-1 receptor agonist, liver injury, weight-loss drugs, GLP-1/GIP therapies, pharmaceutical competition, metabolic diseases, Viking Therapeutics, obesity pipeline
FDA Approves Mirum’s Ctexli as First Treatment for Rare Lipid Disorder CTX
Ctexli, chenodiol, cerebrotendinous xanthomatosis (CTX), FDA approval, Mirum Pharmaceuticals, rare metabolic disorder, lipid storage disease, bile acid therapy
Sionna Therapeutics Raises $191M in Upsized IPO, Aardvark Therapeutics Aims for $100M Listing
Biotech IPOs, Sionna Therapeutics, Aardvark Therapeutics, Cystic Fibrosis, Metabolic Diseases, NASDAQ, Obesity Treatment
Novo Nordisk and Variant Bio Collaborate on Metabolic Disease Research, Focusing on Diverse Populations
Novo Nordisk, Variant Bio, Metabolic disease, Genetic research, Diverse populations, VB-Inference platform, Benefit-sharing program
FDA Approves Ionis’s TRYNGOLZA for Familial Chylomicronemia Syndrome, a Rare Metabolic Disorder
FDA approval, Ionis Pharmaceuticals, TRYNGOLZA, olezarsen, familial chylomicronemia syndrome (FCS), rare metabolic disorder
Relmada Therapeutics Explores Strategic Alternatives Following Discontinuation of Two Phase 3 Trials
Relmada Therapeutics, Phase 3 trials, Strategic alternatives, REL-1017, REL-P11, Central nervous system diseases, Metabolic disorders
FDA Rejects Applied Therapeutics’ Rare Disease Drug Govorestat, Citing Clinical Application Deficiencies
Applied Therapeutics, FDA rejection, govorestat, galactosemia, rare metabolic disease, clinical application deficiencies